Align Technology (ALGN) Shares Sold by Columbus Circle Investors

Columbus Circle Investors trimmed its holdings in shares of Align Technology (NASDAQ:ALGN) by 15.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,166 shares of the medical equipment provider’s stock after selling 18,227 shares during the quarter. Columbus Circle Investors owned 0.13% of Align Technology worth $25,406,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. CAPROCK Group Inc. raised its holdings in shares of Align Technology by 13.2% in the fourth quarter. CAPROCK Group Inc. now owns 1,834 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 214 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Align Technology by 19.2% in the first quarter. Oppenheimer & Co. Inc. now owns 1,335 shares of the medical equipment provider’s stock valued at $335,000 after acquiring an additional 215 shares in the last quarter. Moody Lynn & Lieberson LLC raised its holdings in shares of Align Technology by 9.1% in the fourth quarter. Moody Lynn & Lieberson LLC now owns 2,723 shares of the medical equipment provider’s stock valued at $735,000 after acquiring an additional 228 shares in the last quarter. Global X Management Co. LLC raised its holdings in shares of Align Technology by 10.6% in the fourth quarter. Global X Management Co. LLC now owns 2,399 shares of the medical equipment provider’s stock valued at $533,000 after acquiring an additional 229 shares in the last quarter. Finally, HPM Partners LLC raised its holdings in shares of Align Technology by 19.2% in the fourth quarter. HPM Partners LLC now owns 1,533 shares of the medical equipment provider’s stock valued at $341,000 after acquiring an additional 247 shares in the last quarter. Institutional investors and hedge funds own 79.37% of the company’s stock.

In other news, Director C Raymond Larkin, Jr. sold 15,000 shares of the business’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $264.45, for a total transaction of $3,966,750.00. Following the sale, the director now owns 97,922 shares in the company, valued at $25,895,472.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas M. Prescott sold 82,000 shares of the business’s stock in a transaction dated Monday, April 30th. The stock was sold at an average price of $252.75, for a total value of $20,725,500.00. Following the sale, the director now owns 222,399 shares in the company, valued at approximately $56,211,347.25. The disclosure for this sale can be found here. Insiders have sold 156,742 shares of company stock worth $41,228,991 in the last 90 days. Insiders own 1.40% of the company’s stock.

Several analysts recently weighed in on ALGN shares. Morgan Stanley restated an “equal weight” rating and issued a $220.00 price objective on shares of Align Technology in a report on Thursday, April 19th. Vetr upgraded Align Technology from a “buy” rating to a “strong-buy” rating and set a $302.42 price objective for the company in a report on Monday, March 26th. Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $318.00 price objective for the company in a report on Monday, January 29th. Stephens downgraded Align Technology from an “overweight” rating to an “equal weight” rating and set a $230.00 price objective for the company. in a report on Friday, January 19th. Finally, Credit Suisse Group lifted their target price on Align Technology from $276.00 to $290.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and three have given a strong buy rating to the company’s stock. Align Technology has an average rating of “Buy” and a consensus price target of $270.55.

Align Technology opened at $292.72 on Friday, according to MarketBeat Ratings. Align Technology has a 1 year low of $283.31 and a 1 year high of $291.39. The stock has a market capitalization of $23.08 billion, a price-to-earnings ratio of 68.24, a P/E/G ratio of 2.10 and a beta of 1.48.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Wednesday, April 25th. The medical equipment provider reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.19. Align Technology had a return on equity of 30.36% and a net margin of 16.12%. The company had revenue of $436.92 million for the quarter, compared to analyst estimates of $408.27 million. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. equities research analysts expect that Align Technology will post 4.68 EPS for the current fiscal year.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets a system of clear aligner therapy, intraoral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services. The company's Clear Aligner segment offers Invisalign Full, a treatment used for a range of malocclusion; Invisalign Teen treatment that addresses orthodontic needs of teenage patients, such as compliance indicators, compensation for tooth eruption, and six free single arch replacement aligners; and Invisalign Assist treatment for anterior alignment and aesthetically-oriented cases.

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply